EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications

Mario Sznol iD, Naiyer Rizvi

Journal for ImmunoTherapy of Cancer · 2023

DOI: 10.1136/jitc-2022-006346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2023. Verfasst von Mario Sznol und 1 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cancer Center, Yale University, New Haven, Connecticut, USA mario.sznol@yale.edu. Hauptthemen laut MEDLINE: Melanoma, Kidney Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Various approaches are being explored to address the unmet medical need among patients with advanced cancer who do not respond to immune checkpoint inhibitors. Interleukin-2 has become a prominent focus of preclinical and clinical investigation, because of its known clinical activity, the important role of this cytokine in immune biology, and the ability to engineer variant proteins with potentially improved antitumor immunomodulatory activity and reduced toxicity. Bempegaldesleukin, the first of the modified IL-2 agents to reach phase 3 evaluation in combination with an anti-PD-1, did not improve outcome for patients with metastatic melanoma and renal carcinoma. The disappointing data raise important questions about the potential efficacy of other interleukin-2 variants, however, several of the other variants appear to be sufficiently differentiated in anticipated pharmacokinetic properties and immune modulatory effects to warrant continued clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaKidney NeoplasmsHumansInterleukin-2ImmunotherapyCytokines

Stichwörter der Autor:innen

Clinical Trials as TopicCytokines

Substanzen

Interleukin-2Cytokines

Autor:innen und Institutionen

  • Yale Cancer Center, Yale University, New Haven, Connecticut, USA mario.sznol@yale.edu.
  • Synthekine, Menlo Park, California, USA.

ORCID-Profile: Mario Sznol

Förderung

  • NCATS NIH HHS

Zitieren

APA

Sznol, M., & Rizvi, N. (2023). Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2022-006346

Vancouver

Sznol M, Rizvi N. Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications. Journal for ImmunoTherapy of Cancer. 2023. doi:10.1136/jitc-2022-006346

BibTeX
@article{Sznol2023,
  author = {Sznol, Mario and Rizvi, Naiyer},
  title = {Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  doi = {10.1136/jitc-2022-006346}
}
Kostenlos starten →